Investigating Drug-Induced Dementia Using Microphysiological Systems
Author Information
Author(s): Autar Kaveena Hesperos, Grisales Maria Hesperos, Honore Chelsea Hesperos, Guo Xiufang Hesperos, Morgan David, Michaud Veronique, Turgeon Jacques, Hickman James
Primary Institution: Hesperos
Hypothesis
Can anticholinergic cognitive burden lead to cognitive deficits as assessed by long-term potentiation in a CNS model?
Conclusion
The study found that anticholinergic drugs can exacerbate cognitive decline in patients with early-onset Alzheimer's disease.
Supporting Evidence
- The study utilized a validated hiPSC-cortical neuron model to assess cognitive deficits.
- Caffeine was used to counteract drowsiness caused by anticholinergic drugs.
- Donepezil confirmed that LTP deficits were linked to cholinergic neurotransmission.
- The study demonstrated that ACB drugs can exacerbate LTP deficits when combined with amyloid-beta42 oligomers.
Takeaway
Some medications can make it harder for people to think clearly, and this study shows how we can test this using special brain models.
Methodology
The study used a human induced-pluripotent stem cell model to evaluate the effects of anticholinergic drugs on cognitive function through long-term potentiation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website